GIVEAWAY: Omnipod Pullover

A few years ago I spoke at an event and came home with this beautiful and incredibly comfortable pullover for Arden - but it didn’t fit her and so it went to live in her closet. I present it here today, never worn, soft as a cloud and ready for the winner of this Giveaway.

item: The giveaway is for one pullover, Ladies Extra Small. It is the shirt you see in the photos below. The item has no cash value. Complete giveaway rules are here.

shipping: Anyone can enter but if you are outside of the United States I may ask you to help with shipping, sound fair?

Here’s how you can accumulate entry points (the more points you have, the better your chances are of being drawn at random).

• Leave a review for the Juicebox Podcast on Apple Podcasts (iTunes) you’ll receive, 5 points.

• Leave a review on the Bold With Insulin Facebook page, 3 points.

• Subscribe to the Juicebox Podcast in your favorite podcast app, 1 point.

• Email, text or tell someone about the Juicebox Podcast and then help them to subscribe, 1 point.

All entries are made through the Rafflecopter app below. Please note that review entries require you to leave your username (used for the review) so I can verify your entry.

a Rafflecopter giveaway

View fullsize

Apple Reviews have three parts. Click to enlarge.

Try a free, no obligation Omnipod demo today.

---

Bump and Nudge

Mini-Post: Bump and Nudge

View fullsize

Arden woke up for school at 6:30 am with a BG of 71 but wasn’t planning on eating before she left for school. About 45 minutes later her BG began to drift lower and she still wasn’t hungry. The drift had momentum because her basal rate increases at 7 am for her school day insulin needs. So we bumped the number with chewable vitamins - just 5 carbs but they worked perfectly. Her BG went to 101 and then drifted back to 91. She did not eat until noon and never experienced a low.

To learn more about bumping and nudging check out episode #225 of the Juicebox Podcast (look down). If you like it consider heading back to episode 210 and listening to the entire Diabetes Pro Tip Series.

---

Sanofi to Exit Diabetes Research

from WallStreetJournal.com

“To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history. As tough a choice as that is, we’re making that choice.”

— Sanofi Chief Executive Paul Hudson

The maker of the world’s top-selling insulin has given up on finding new diabetes drugs. which makes Lantus, said Monday it would stop investing in diabetes research after years of frustrated attempts to bring a fresh blockbuster to the market.

The decision is part of a broader strategic overhaul by new Chief Executive Paul Hudson, who hopes to reinvigorate growth at the French health-care giant by focusing on fewer, more specialized disease areas such as cancer—mirroring a move being made across the drug industry.

Read the entire article here

---

FDA approves Fiasp in insulin infusion pumps for adults

FDA approves Fiasp® for use in insulin infusion pumps for adults with type 1 or type 2 diabetes

press release

PLAINSBORO, N.J., Oct. 22, 2019 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has expanded the label for Fiasp® (insulin aspart injection) 100 u/mL to include use in insulin infusion pumps for the improvement of glycemic control in adults with type 1 or type 2 diabetes.1 Fiasp®, a rapid-acting insulin, was approved by the FDA in 2017 for use by intravenous infusion under supervision by a healthcare professional or by subcutaneous multiple daily injection (MDI) in adults with diabetes.

There are estimated to be more than 350,000 insulin infusion pump users in the U.S.2,3,4 An insulin pump is a small, programmable, battery-operated device that delivers insulin under the skin. Fiasp® should be used in accordance with the insulin pump's instructions for use. Fiasp® is available in multiple dosing options for multiple daily injections (MDI) as well as continuous subcutaneous insulin infusion1:

• 10 mL vial for use in insulin pumps or MDI

• 3 mL FlexTouch® for MDI

• 3 mL PenFill® Cartridge for NovoPen Echo for MDI

"People living with diabetes are looking for treatment options that fit into their lifestyles and shifting schedules, and for many, an insulin pump is an important part of their regimen," said Todd Hobbs, vice president and U.S. chief medical officer of Novo Nordisk. "Since the launch of Fiasp®, we've heard time and again from the diabetes community about the need to make it available for adult insulin pump users. This label update will now enable adult patients to use Fiasp® in their pumps, which is an important part of our ongoing commitment to patient choice and meeting the needs of people living with type 1 and type 2 diabetes." 

The label change is based on the FDA's review of data from the onset 5 clinical trial, which confirmed the efficacy and safety of Fiasp® when used in insulin infusion pumps in adults with diabetes. 5 Fiasp® has been shown to be well-tolerated and effective in pumps releasing steady doses throughout the day and mealtime doses during meals. The pump should be programmed based on guidance from healthcare providers and the pump maker's instructions. 

---

FAA to allow pilots with diabetes to fly commercial jets

from CNN.com

The Federal Aviation Administration is set to allow pilots with insulin-treated diabetes to apply to fly commercial airliners, according to a Department of Transportation official who spoke with CNN. 

The new protocol, which could be announced as early as next week, will allow pilots with insulin-treated diabetes to apply for a first- or second-class medical certificate, which is required to fly commercially.

““Many private pilots who are insulin dependent have been flying safely since 1996. With medical advancements, such as continuous glucose monitoring along with proper protocols, the FAA’s impending proposal should help many highly qualified pilots fly commercially,””

— Jim Coon, the group's senior vice president of government affairs.

Since 1996, pilots with insulin-treated diabetes have been allowed to act as pilot-in-command of an airplane in the United States, but only on private flights. They could not act as pilots on airliners or other commercial flights. The FAA maintained this position even as countries like the United Kingdom and Canada gradually allowed pilots with diabetes to fly commercially, provided there was a second pilot in the cockpit.

The Aircraft Owners and Pilots Association, which supported the change, applauded the forthcoming decision.

You can read the rest of the article here on CNN.com.

Bonus content

John lost his career as an airline pilot when he was diagnosed with type 1 diabetes. He hopes that one day he can regain his status and continue flying for a living.

You can hear John’s story on episode 172 of the Juicebox Podcast, ‘John Loses His Wings’.

---